L3VLUP
ProSign in

DXCM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DXCMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DXCM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterDXCMLLY
Q3 202025 holders, $9.9bn33 holders, $14.1bn
Q4 202024 holders, $8.8bn29 holders, $17.3bn
Q1 202122 holders, $8.4bn24 holders, $23.0bn
Q2 202117 holders, $9.4bn24 holders, $27.8bn
Q3 202122 holders, $12.0bn31 holders, $29.9bn
Q4 202133 holders, $11.1bn31 holders, $34.7bn
Q1 202225 holders, $9.9bn24 holders, $35.3bn
Q2 202229 holders, $5.6bn33 holders, $42.7bn
Q3 202224 holders, $6.0bn31 holders, $43.4bn
Q4 202226 holders, $8.3bn31 holders, $46.6bn
Q1 202333 holders, $8.9bn33 holders, $44.3bn
Q2 202328 holders, $8.9bn37 holders, $59.6bn
Q3 202332 holders, $6.9bn44 holders, $67.6bn
Q4 202328 holders, $10.0bn45 holders, $73.6bn
Q1 202429 holders, $10.7bn41 holders, $95.3bn
Q2 202430 holders, $8.8bn43 holders, $110bn
Q3 202426 holders, $4.7bn45 holders, $107bn
Q4 202431 holders, $5.1bn46 holders, $93.9bn
Q1 202524 holders, $3.7bn42 holders, $98.4bn
Q2 202520 holders, $4.5bn43 holders, $93.2bn
Q3 202529 holders, $4.1bn39 holders, $86.7bn
Q4 202528 holders, $4.6bn41 holders, $123bn
Q1 202625 holders, $4.6bn39 holders, $106bn
Q2 202617 holders, $4.6bn44 holders, $132bn
DXCM

Dexcom Inc

Holders
25
Reported value
$4.6bn
Buyers
17
Sellers
18

Breadth -1 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DXCM (5)

Baillie Gifford & Co, Balyasny Asset Management LLC, First Eagle Investment Management LLC, MFS Investment Management, Winton Group Ltd

Only LLY (19)

ARK Investment Management LLC, Artisan Partners LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Marshall Wace LLP, Point72 Asset Management LP, Polen Capital Management LLC, Soros Fund Management LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Voloridge Investment Management LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →